VERAGENETICA
VERAGENETICAServicegroepenPatiëntenkluisLangleven PlannerPersoonlijk GezondheidsbeheerPremium Programma'sVerblijvenOns TeamBlogContact
Klinisch Onderzoek

Blog & Nieuws

De nieuwste wetenschappelijke artikelen en nieuws uit de wereld van stamceltoepassingen, genetica en biotechnologie.

PGT-A: Confirm Your Embryos' Chromosomal Integrity Before Transfer
21 september 2026

PGT-A: Confirm Your Embryos' Chromosomal Integrity Before Transfer

PGT-A (Preimplantation Genetic Testing for Aneuploidy) evaluates the chromosomal integrity of your embryos before transfer, using next-generation sequencing to improve IVF success rates.

Lees Artikel
mRNA Cancer Vaccines and Neoantigens: What Did the KEYNOTE-942 Trial Show in Melanoma?
7 augustus 2026

mRNA Cancer Vaccines and Neoantigens: What Did the KEYNOTE-942 Trial Show in Melanoma?

The combination of mRNA-4157/V940 and Keytruda reduced the risk of recurrence in high-risk melanoma in the Phase 2b KEYNOTE-942 trial. Phase 3 process and current status.

Lees Artikel
For Which Types of Cancer Is a Personalized Vaccine Approach Being Evaluated? Mutation Burden Guide
5 augustus 2026

For Which Types of Cancer Is a Personalized Vaccine Approach Being Evaluated? Mutation Burden Guide

Tumor mutation burden is associated with immunotherapy response. The scientific rationale for a personalized vaccine approach in cancers such as melanoma, NSCLC, and glioblastoma.

Lees Artikel
FDA-Approved Cancer Vaccine Sipuleucel-T: Dendritic Cell Therapy for Prostate Cancer
3 augustus 2026

FDA-Approved Cancer Vaccine Sipuleucel-T: Dendritic Cell Therapy for Prostate Cancer

Sipuleucel-T (Provenge) is the first FDA-approved cellular cancer immunotherapy. Dendritic cell technology, the IMPACT study, and its use in prostate cancer.

Lees Artikel
What Is a Personalized Cancer Vaccine? Tumor Lysate, Dendritic Cells, and the mRNA Approach
31 juli 2026

What Is a Personalized Cancer Vaccine? Tumor Lysate, Dendritic Cells, and the mRNA Approach

Personalized cancer vaccines combine tumor lysate, dendritic cell, and mRNA neoantigen technologies. Their scientific basis and current status of clinical trials.

Lees Artikel
DCVax-L and Dendritic Cell Vaccine for Glioblastoma: Phase 3 Data and Approval Status
29 juli 2026

DCVax-L and Dendritic Cell Vaccine for Glioblastoma: Phase 3 Data and Approval Status

DCVax-L is a dendritic cell + tumor lysate vaccine being studied in patients with glioblastoma. Phase 3 results, survival data, and current FDA/MHRA approval status

Lees Artikel
VERA|GENETICA

Gepersonaliseerde gezondheidsbenaderingen op basis van genetische, biologische en klinische gegevens.

Mondiale Coördinaten

+90 542 659 85 70
info@veradoctors.com

Klinische processen worden uitgevoerd in overeenstemming met de relevante gezondheidsautoriteiten en geldende gezondheidsnormen.

© 2026 Vera Genetica Longevity Group. Geregistreerd volgens de normen van het Turkse Ministerie van Volksgezondheid.